Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serious fatal and nonfatal non-AIDS-defining illnesses in Europe.
Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. Mocroft A, et al. Among authors: rakhmanova a. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70. doi: 10.1097/QAI.0b013e3181e9be6b. J Acquir Immune Defic Syndr. 2010. PMID: 20700060
The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. Mocroft A, et al. Among authors: rakhmanova a. Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26. Antivir Ther. 2012. PMID: 23013779
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. Mocroft A, et al. Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17. Lancet HIV. 2016. PMID: 26762990 Clinical Trial.
Natural history of HIV-control since seroconversion.
Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord. Madec Y, et al. AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01. AIDS. 2013. PMID: 23912979
Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.
Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study; CASCADE Collaboration in EuroCoord. Huang X, et al. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a. J Acquir Immune Defic Syndr. 2013. PMID: 23221982
Risk of tuberculosis following HIV seroconversion in high-income countries.
Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord. Lodi S, et al. Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31. Thorax. 2013. PMID: 23117980 Free article.
170 results